Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Quick Comparison Feature CagriSema Retatrutide Development owner Novo Nordisk Eli Lilly Core strategy Combination therapy Single-molecule multi-agonist Pathways Amylin + GLP-1 GIP + GLP-1 + glucagon Main components Cagrilintide + semaglutide Retatrutide (LY3437943) 2026 status Phase 3 / regulatory-watch candidate Phase 3 TRIUMPH program Best-fit research question Can amylin extend GLP-1 results
While gastrointestinal side effects like nausea and diarrhea are well-documented, some patients report experiencing leg cramps during treatment
10.1182/blood.v31.3.388.388 Blood
s-acetyl-glutathione-synergy-patiented *These statements have not been evaluated by the Food and Drug Administration
CLA helps reduce fat deposits, increase muscle mass, and improve metabolism
Another study indicates that over 90% of healthcare interventions examined in recent Cochrane Reviews lack robust support from high-quality evidence, and there is insufficient reporting of associated harms (297)
